COSMO BIO COMPANY, LIMITED【JP:3386】Stock Price

Cosmo Bio is primarily engaged in the import and sale of research reagents, equipment, and contract services related to life sciences. The company procures products from domestic and international suppliers, offers proprietary products, and provides contract services including drug discovery support. Its customers are mainly researchers at educational institutions, public research organizations, and corporations.

To meet researchers' needs, the company works to expand its product lineup. To provide products and support quickly to researchers throughout Japan, it conducts wholesale sales through distributors nationwide. A key feature of its business is efficiently matching specialized products and information with customer needs.

BM Equipment Co., Ltd., a subsidiary of Cosmo Bio, is an import trading company that primarily handles life science research equipment and consumables. COSMO BIO USA, INC., based in California, sells reagents and equipment manufactured in Japan to overseas markets.

Proteintech Japan Inc. is a joint venture with Proteintech Group, Inc., providing technical support and sales promotion for its products. To strengthen domestic sales operations, the company has consolidated three group companies on the same floor to improve operational efficiency and productivity.

Cosmo Bio introduces over 10 million products from approximately 500 companies worldwide and provides them to researchers. For needs that cannot be met by existing products, the company responds by offering proprietary products and services. As a life sciences trading company, it supplies research reagents, equipment, and consumables.

The company also operates drug discovery research support and contract services, including conducting experiments such as drug candidate screening and biomarker analysis. It also engages in export operations for research reagents and equipment, with overseas sales centered on COSMO BIO USA.

In manufacturing and development, the company partners with research institutions such as universities to develop and manufacture proprietary products and provide contract services. It offers a wide range of services including primary cell culture manufacturing, custom peptide synthesis, and antibody production services.

Cosmo Bio aims to support advances in life sciences and pursue sustainable growth. The company prioritizes establishing itself as a trusted partner through improved product and service quality, and providing added value that is recognized by society.

As the second phase of its three-year plan, the company is expanding proprietary products and strengthening international operations. It is reviewing its organizational structure and working to enhance shareholder returns and create new businesses to improve corporate value. Through these efforts, the company is expanding its revenue sources.

To create new business foundations, Cosmo Bio is strengthening seed exploration and promoting industry-academia-government collaboration. Through the deployment of its platform business "Scientist³," the company is developing new businesses that will become the next pillar of revenue. It is maintaining and strengthening market competitiveness while actively pursuing collaboration with other companies.

In strengthening its existing business foundation, the company is introducing cutting-edge digital technology and enhancing its trading company functions. It is improving proposal capabilities and information gathering both domestically and internationally to provide services that meet customer needs. At its Sapporo facility, the company is advancing new technology adoption and operational efficiency to improve profitability and added value.

To enhance corporate value, Cosmo Bio is promoting operational efficiency and creating synergies. Through strengthening its human resources base and flexible implementation of remote work systems, the company aims to improve productivity. The company also contributes to solving social issues through business activities that consider sustainability.

The company targets an ROE of 8% or higher and aims to reduce capital costs, with a stock price level targeting a PBR of 1.0x or above. Through enhanced investor relations activities, strengthened shareholder returns, and operational efficiency improvements via digital transformation, the company is working to increase profitability in existing businesses and create new ones.